This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Nov;19(11):755.

doi: 10.1038/d41573-020-00165-2.

Selectively triggering mitotic failure

Sarah Crunkhorn

PMID: 32943764
DOI: 10.1038/d41573-020-00165-2

Comment

Selectively triggering mitotic failure

Sarah Crunkhorn. Nat Rev Drug Discov. 2020 Nov.

. 2020 Nov;19(11):755.

doi: 10.1038/d41573-020-00165-2.

Author

Sarah Crunkhorn

PMID: 32943764
DOI: 10.1038/d41573-020-00165-2

No abstract available

PubMed Disclaimer

Comment on

TRIM37 controls cancer-specific vulnerability to PLK4 inhibition.
Meitinger F, Ohta M, Lee KY, Watanabe S, Davis RL, Anzola JV, Kabeche R, Jenkins DA, Shiau AK, Desai A, Oegema K. Meitinger F, et al. Nature. 2020 Sep;585(7825):440-446. doi: 10.1038/s41586-020-2710-1. Epub 2020 Sep 9. Nature. 2020. PMID: 32908304 Free PMC article.
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.
Yeow ZY, Lambrus BG, Marlow R, Zhan KH, Durin MA, Evans LT, Scott PM, Phan T, Park E, Ruiz LA, Moralli D, Knight EG, Badder LM, Novo D, Haider S, Green CM, Tutt ANJ, Lord CJ, Chapman JR, Holland AJ. Yeow ZY, et al. Nature. 2020 Sep;585(7825):447-452. doi: 10.1038/s41586-020-2690-1. Epub 2020 Sep 9. Nature. 2020. PMID: 32908313 Free PMC article.

Similar articles

TRIM37 controls cancer-specific vulnerability to PLK4 inhibition.
Meitinger F, Ohta M, Lee KY, Watanabe S, Davis RL, Anzola JV, Kabeche R, Jenkins DA, Shiau AK, Desai A, Oegema K. Meitinger F, et al. Nature. 2020 Sep;585(7825):440-446. doi: 10.1038/s41586-020-2710-1. Epub 2020 Sep 9. Nature. 2020. PMID: 32908304 Free PMC article.
TRIM proteins and diseases.
Watanabe M, Hatakeyama S. Watanabe M, et al. J Biochem. 2017 Feb 1;161(2):135-144. doi: 10.1093/jb/mvw087. J Biochem. 2017. PMID: 28069866 Review.
Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.
Glass DJ. Glass DJ. Nat Cell Biol. 2003 Feb;5(2):87-90. doi: 10.1038/ncb0203-87. Nat Cell Biol. 2003. PMID: 12563267 Review.
Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Qin Y, Cui H, Zhang H. Qin Y, et al. Technol Cancer Res Treat. 2016 Oct;15(5):707-15. doi: 10.1177/1533034615595903. Epub 2015 Jun 25. Technol Cancer Res Treat. 2016. PMID: 26113559
AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells.
Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH. Krawiec BJ, et al. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1555-67. doi: 10.1152/ajpendo.00622.2006. Epub 2007 Jan 30. Am J Physiol Endocrinol Metab. 2007. PMID: 17264220

See all similar articles

References

1. Yeow, Z. et al.Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. Nature https://doi.org/10.1038/s41586-020-2690-1 (2020)
1. Meitinger, F. et al. TRIM37 controls cancer-specific vulnerability to PLK4 inhibition. Nature https://doi.org/10.1038/s41586-020-2710-1 (2020)

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information